TY - JOUR
T1 - Clinical use and predictors of outcome in venoarterial extracorporeal membrane (VA ECMO)
T2 - insights from VERGE (VA ECMO Registry of Germany)
AU - VERGE Study Group
AU - Wengenmayer, Tobias
AU - Staudacher, Dawid L
AU - Philipp, Alois
AU - Tigges, Eike
AU - Dettling, Angela
AU - Busse, Hendrik
AU - Kriege, Marc
AU - Padberg, Jan-Sören
AU - Voigt, Ingo
AU - Scherer, Clemens
AU - Graf, Tobias
AU - Scharpf, Dominik
AU - Noack, Peter
AU - Britsch, Simone
AU - Michels, Guido
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025
Y1 - 2025
N2 - The VA ECMO Registry of Germany (VERGE, http://va-ecmo-register.de/ ) is a prospective, multicenter, investigator-driven registry of Venoarterial Extracorporeal Membrane Oxygenation (VA ECMO) all-comers, free from industrial support. VERGE is Germany's first multicenter registry to systematically gather and analyze data from various centers on the clinical use of VA ECMO. This first report compromises data from 581 VA ECMO patients from 2022. Median age was 60 years, hospital survival was 42% and 25% were female. The leading indication for VA ECMO was extracorporeal cardiopulmonary resuscitation (ECPR) followed by VA ECMO in shock (48.9 and 34.9%, respectively). Hospital survival of ECPR was significantly worse compared to shock (28 and 55%, respectively, p < 0.001). Age, pH, and lactate before cannulation all significantly correlated independently with hospital survival (p < 0.001). In VERGE, no patients with pH below 6.7 or lactate above 25 mmol/l survived.
AB - The VA ECMO Registry of Germany (VERGE, http://va-ecmo-register.de/ ) is a prospective, multicenter, investigator-driven registry of Venoarterial Extracorporeal Membrane Oxygenation (VA ECMO) all-comers, free from industrial support. VERGE is Germany's first multicenter registry to systematically gather and analyze data from various centers on the clinical use of VA ECMO. This first report compromises data from 581 VA ECMO patients from 2022. Median age was 60 years, hospital survival was 42% and 25% were female. The leading indication for VA ECMO was extracorporeal cardiopulmonary resuscitation (ECPR) followed by VA ECMO in shock (48.9 and 34.9%, respectively). Hospital survival of ECPR was significantly worse compared to shock (28 and 55%, respectively, p < 0.001). Age, pH, and lactate before cannulation all significantly correlated independently with hospital survival (p < 0.001). In VERGE, no patients with pH below 6.7 or lactate above 25 mmol/l survived.
UR - https://www.scopus.com/pages/publications/105003406500
UR - https://www.mendeley.com/catalogue/5c191b6b-a820-39a1-86c9-469ad5a2c32a/
U2 - 10.1007/s00392-025-02650-3
DO - 10.1007/s00392-025-02650-3
M3 - Journal articles
C2 - 40261425
SN - 1861-0684
JO - Clinical Research in Cardiology
JF - Clinical Research in Cardiology
M1 - 102619
ER -